Copyright © The Nobel Foundation 1989. We thank the Nobel Foundation, Stockholm, for permission to print this lecture.
Selective Inhibitors of Dihydrofolate Reductase (Nobel Lecture)†
Article first published online: 30 DEC 2003
Copyright © 1989 by VCH Verlagsgesellschaft mbH, Germany
Angewandte Chemie International Edition in English
Volume 28, Issue 7, pages 879–885, July 1989
How to Cite
Hitchings, G. H. (1989), Selective Inhibitors of Dihydrofolate Reductase (Nobel Lecture). Angew. Chem. Int. Ed. Engl., 28: 879–885. doi: 10.1002/anie.198908791
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
- Manuscript Received: 27 JAN 1989
- Dihydrofolate reductase;
- Nobel lecture;
- Drug research;
Purine and pyrimidine derivatives acting as nucleic base antagonists and inhibitors of dihydrofolate-reductase(DHFR), which is an essential enzyme for nuclei acid synthesis in vivo, have opened up access to the chemotherapy of cancer, particularly leukemia, to immunosuppression, and to the treatment of gout and virus diseases. Examples from the Nobel lectures of Gertrude Elion and George Hitchings are the clinically extremely important antiviral agent acyclovir 1 (purine derivative) and the DHFR inhibitor trimetrexate 2 (pyrimidine derivative).